Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 692-842-6 | CAS number: 1312296-85-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
Test material
- Details on test material:
- - CAS No.: 1312296-85-7
- Purity: 100.4 g/100 g determined by 1H-NMR-analysis.
- Homogeneity: The test item was homogeneous by visual inspection.
- Storage stability: The stability of the test item under storage conditions over the study period was guaranteed by the sponsor, and the sponsor holds this responsibility.
- Storage conditions: Room temperature; under N2
- Physical state/color: Solid/beige
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga GmbH, Sulzfeld, Germany
- Age at study initiation: approx. 10 weeks
- Weight at study initiation: animals of comparable weight (± 20% of the mean weight); mean weights: 300 mg/kg bw group 1: 186.3 g; 2000 mg/kg bw group: 166.3 g; 300 mg/kg bw group 2: 166.7 g
- Fasting period before study: Feed was withdrawn from the animals at least 16 hours before administration, but water was available ad libitum.
- Housing: single housing in Makrolon cage, type III
- Diet: VRF1(P); SDS Special Diets Services ad libitum (except during fasting period)
- Water: tap water ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- (deionized)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 300 mg/kg bw groups: 3 g/100 mL; 2000 mg/kg bw group: 20 g/100 mL
- Justification for choice of vehicle: Solution in deionized water
ADMINISTRATION VOLUME: 10 mL/kg bw
CLASS METHOD
- Rationale for the selection of the starting dose: Based on available acute oral toxicity data with sodium dicyanamid (LD50 = 725 mg/kg) the starting dose was chosen to be 300 mg/kg bw. - Doses:
- 300 and 2000 mg/kg bw
- No. of animals per sex per dose:
- 300 mg/kg bw: 6 females; 2000 mg/kg bw: 3 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: A check for any dead or moribund animals was made at least once each workday. Clinical signs were recorded several times on the day of administration, and at least once daily thereafter each workday for the individual animals. Individual body weights were determined shortly before administration (day 0), weekly thereafter and on the last day of observation.
- Necropsy of survivors performed: yes
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals died in the 2000 mg/kg test group within one day after application. No mortality occurred in both 300 mg/kg test groups.
- Clinical signs:
- other: In the animals of the 2000 mg/kg bw test group poor general state was noted from hour 1 until hour 3 or 4 after application. In one of these animals impaired general state was noted at hour 0. Dyspnoea and piloerection was noted in all animals beginning w
- Gross pathology:
- In all animals which died in the 2000 mg/kg test group gaseous stomach, red discoloration of the small intestine and yellowish discoloration of the stomach content were noted at the necropsy. In one of these animals additionally dark spotted discoloration of all lung lobes was noted. In another female additionally red discoloration of the glandular stomach was noted after the animal died.
There were no macroscopic pathological findings in animals sacrificed at the end of the observation period ( 6 females of the 300 mg/kg bw groups).
Any other information on results incl. tables
MORTALITY:
Dose (mg/kg bw): |
2000 |
300 |
300 |
Sex: |
female |
female |
female |
Administration: |
1 |
1 |
2 |
No. of animals: |
3 |
3 |
3 |
Mortality (animals): |
3 |
No mortality |
No mortality |
MAXIMUM INCIDENCE OF CLINICALSIGNS:
Dose (mg/kg bw): |
2000 |
|||
Sex: |
female |
|||
Administration: |
1 |
|||
No. of animals: |
3 |
|||
Animal No.:
|
1 |
2 |
3 |
|
Abnormalities: |
|
|
|
|
Impaired general state: |
- |
- |
h0 |
|
Poor general state: |
h1 - h3 |
h1 - h4 |
h1 - h4 |
|
Dyspnoea: |
h1 - h3 |
h1 - h4 |
h0 - h5 |
|
Piloerection: |
h1 - h3 |
h1 - h4 |
h0 - h5 |
|
Abdominal position: |
h1 - h2 |
- |
h3 - h5 |
|
Lateral position: |
h3 |
- |
- |
|
Extension spasm: |
h3 |
- |
h3 - h5 |
|
Rolling convulsions: |
h1 - h2 |
h3 - h4 |
h1 - h2 |
|
Tremor: |
- |
h2 |
- |
|
Straub phenomenon: |
- |
- |
h3 - h5 |
|
Mortality: |
h3 |
h5 |
d1 |
|
|
||||
Dose (mg/kg bw): |
300 |
|||
Sex: |
female |
|||
Administration: |
1 |
|||
No. of animals: |
3 |
|||
Animal No.:
|
1 |
2 |
3 |
|
Abnormalities: |
- |
- |
- |
|
|
||||
Dose (mg/kg bw): |
300 |
|||
Sex: |
female |
|||
Administration: |
2 |
|||
No. of animals: |
3 |
|||
Animal No.:
|
1 |
2 |
3 |
|
Abnormalities: |
|
|
|
|
Impaired general state: |
h3 - h5 |
h5 |
h5 |
|
Poor general state: |
- |
h2 - h4 |
h2 - h4 |
|
Dyspnoea: |
h3 - h5 |
h2 - h5 |
h2 - h5 |
|
Piloerection: |
h3 - h5 |
h2 - h5 |
h2 - h5 |
|
Staggering: |
- |
h2 - h4 |
h2 - h4 |
|
Tremor: |
- |
- |
h2 |
BODY WEIGHT CHANGES:
Individual body weights |
|||||||||||||||
Dose (mg/kg bw): |
2000 |
300 |
300 |
||||||||||||
Administration: |
1 |
1 |
2 |
||||||||||||
Animal No.: |
1 |
2 |
3 |
mean |
SD |
1 |
2 |
3 |
mean |
SD |
1 |
2 |
3 |
mean |
SD |
Body weight at study day (g): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0 |
166 |
170 |
163 |
166.3 |
3.51 |
191 |
187 |
181 |
186.3 |
5.03 |
174 |
158 |
168 |
166.7 |
8.08 |
1 |
- |
- |
156 |
- |
|
- |
- |
- |
- |
|
- |
- |
- |
- |
|
7 |
- |
- |
- |
- |
|
203 |
194 |
185 |
194.0 |
9.00 |
189 |
186 |
196 |
190.3 |
5.13 |
14 |
- |
- |
- |
- |
|
204 |
199 |
196 |
199.7 |
4.04 |
200 |
199 |
206 |
201.7 |
3.79 |
GROSS PATHOLOGY:
Dose (mg/kg bw): |
2000 |
300 |
300 |
||||||
Administration: |
1 |
1 |
2 |
||||||
No. of animals: |
3 |
3 |
3 |
||||||
Animal No.: |
1 |
2 |
3 |
1 |
2 |
3 |
1 |
2 |
3 |
Macroscopic pathologic abnormalities: |
Stomach: gaseous, content yellowish discolored; small intestine: red discolored |
Stomach: gaseous, content yellowish discolored; |
Lung: dark spotted discoloration of all lobes; |
- |
- |
- |
- |
- |
- |
Applicant's summary and conclusion
- Interpretation of results:
- moderately toxic
- Remarks:
- Migrated information
- Conclusions:
- Under the conditions of this study the median lethal dose of the test substance after oral administration was found to be greater than 300 mg/kg bw and less than 2000 mg/kg bw in rats.
- Executive summary:
The study was performed according to OECD guideline 423 in compliance with GLP.
In this acute oral toxicity study performed according to the Acute Toxic Class method, doses of 2000 and 300 mg/kg bw of the test item (preparations in doubly deionized water) were administered to three test groups of three fasted Wistar rats each (2000 mg/kg bw in 3 females, 300 mg/kg bw in 6 females) by gavage in a sequential manner.
The following test substance-related clinical observations were recorded:
- 2000 mg/kg (single test group):
Mortality in all animals, impaired general state in one out of three animals, poor general state in all animals, dyspnoea in all animals, piloerection in all animals, abdominal position in two out of three animals, lateral position in one out of three animals, extension spasm in two out of three animals, rolling convulsions in all animals, tremor in one out of three animals, Straub phenomenon in one out of three animals.
- 300 mg/kg (first test group):
No mortality occurred. No clinical signs were observed in the first test group dosed with 300 mg/kg bw.
- 300 mg/kg (second test group):
No mortality occurred, impaired general state in all animals, poor general state in two out of three animals, dyspnoea in all animals, piloerection in all animals, staggering in two out of three animals, tremor in one out of three animals.
The mean body weight of the surviving animals increased within the normal range throughout the study period.
The following macroscopic pathological findings were observed in the animals that died (2000 mg/kg; 3 females):
Dark spotted discoloration of all lung lobes, yellowish discoloration of the stomach content, gaseous stomach, red discoloration of the glandular stomach, red discoloration of the small intestine.
There were no macroscopic pathological findings in animals sacrificed at the end of the observation period (300 mg/kg; 6 females).
Conclusion: The acute oral LD50 was calculated to be LD50, oral, rat > 300 mg/kg < 2000 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Deși ECHA oferă o varietate bogată de materiale online în limba dumneavoastră, o parte din conţinutul acestei pagini este disponibil numai în limba engleză. Pentru mai multe informaţii referitoare la practica multilingvă a ECHA.
Bun venit pe site-ul ECHA. Acest site nu este deplin acceptat în Internet Explorer 7 (și versiuni anterioare). Vă rugăm să vă actualizați versiunea de Internet Explorer.
Acest site folosește module cookie pentru a garanta că aveți parte de cea mai bună experiență pe paginile noastre.
Aflați mai multe despre cum folosim modulele cookie.